Prostaglandin F2-alpha eye drops (Bimatoprost) in thyroid eye disease: a randomised controlled double blind crossover trial - BIMA STUDY: Bimatoprost Eye Drops in Thyroid Eye Disease

Cardiff University0 个研究点目标入组 31 人开始时间: 2014年4月1日最近更新: 2019年6月30日

适应症

试验速览

暂无简介。

•1.Stable TED with no reported change in proptosis for at least 6 months
•2.Clinical activity score <3
•3.Proptosis (subjective unilateral proptosis confirmed by asymmetry in exophthalmometry of >2mm OR greater than 20 mm on exophthalmometry measurement in one eye)
•4.Euthyroid (FT3 and FT4 in the reference range).
•5. If female, must be using a reliable form of contraception during the trial, e.g. oral contraceptive and condom, intra-uterine device (IUD) and condom, diaphragm with spermicide and condom.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 11

•1.Age <18 yrs
•2.Dysthyroid optic neuropathy unless previously treated
•3.Pregnancy or lactation
•4.Previous Corneal Herpes Simplex infection
•5.On therapy for glaucoma or intraocular hypertension
•6.Less than 6 months from prior steroid use
•7.Aphakia, pseudophakia with torn posterior lens capsule or anterior chamber lenses
•8.Patient with risk factors for cystoid macular oedema, iritis or uveitis
•9.Severe Asthma (risk of severe allergic reaction to medication).
•10.Previous allergy to Bimatoprost or preservative.

发起方